Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Soleno Therapeutics (SLNO) Work In Process (2025)

Soleno Therapeutics (SLNO) has disclosed Work In Process for 1 consecutive years, with $2.7 million as the latest value for Q4 2025.

For Q4 2025, Work In Process changed N/A year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, changed N/A, while the annual FY2025 figure was $2.7 million, N/A changed from the prior year.
Work In Process hit $2.7 million in Q4 2025 for Soleno Therapeutics, up from $2.0 million in the prior quarter.
Across five years, Work In Process topped out at $2.7 million in Q4 2025 and bottomed at $950000.0 in Q2 2025.